



# Take a closer look at the reality of SpA



## Spondyloarthritis Scientific Forum 04–05 December 2015

### DAY 1: 04 DECEMBER

08.00–09.00 *Registration and coffee*

09.00–09.05 Welcome from the Spanish Society of Rheumatology

S Muñoz-Fernández – Past-President of the Spanish Society of Rheumatology (Spain)

09.05–09.15 Chair's welcome and introduction

P Emery (UK), F Van den Bosch (Belgium)

Session 1:  
**Understanding the spectrum and pathophysiology of spondyloarthritis**

Session chairs:  
P Emery (UK), F Van den Bosch (Belgium)

09.15–10.25 Defining the spectrum of spondyloarthritis: recent advances & clinical implications

F Van den Bosch (Belgium)

Understanding the pathophysiology of spondyloarthritis

D Elewaut (Belgium)

Q&A session

Moderators: P Emery (UK), F Van den Bosch (Belgium)

10.25–10.45 *Coffee break*

Session 2:  
**Psoriatic arthritis: diagnosis, assessment, and principles of management**

Session chairs:  
P Emery (UK), F Van den Bosch (Belgium)

10.45–13.00 Challenges and opportunities in the diagnosis of psoriatic arthritis: the rheumatologist's perspective

G Ferraccioli (Italy)

A holistic approach to psoriatic arthritis: the dermatologist's perspective

W Boehncke (Switzerland)

Treating to target and treatment guidelines in psoriatic arthritis: updates, consensus, and controversies

P Nash (Australia)

Q&A session

Moderator: F Van den Bosch (Belgium)

Management of psoriatic arthritis: current and future perspectives

D Baeten (Netherlands)

Debate: methotrexate should remain a cornerstone of psoriatic arthritis treatment algorithms

Pro: G Ferraccioli (Italy)  
Contra: P Nash (Australia)  
Moderators: P Emery (UK), F Van den Bosch (Belgium)

Q&A session

Moderators: P Emery (UK), F Van den Bosch (Belgium)

13.00–14.00 *Lunch*

Session 3:  
**Parallel workshop sessions: optimizing the management of spondyloarthritis in clinical practice**  
(Delegates will attend 2 workshops, each 45 mins in length, with 10 mins allowed to move between breakout rooms)

14.00–15.40 **Workshop sessions:**

1. Practical guidance on using biologics in spondyloarthritis
2. Early diagnosis and treatment of spondyloarthritis
3. Treating to target and aligning regional treatment practices with international guidelines: challenges and perspectives
4. What can dermatologists learn from rheumatologists, and vice-versa?
5. Imaging in spondyloarthritis: what to look for and pitfalls to avoid

D Baeten (Netherlands), J Cañete (Spain)  
F Van den Bosch (Belgium), D Elewaut (Belgium)  
P Nash (Australia)

G Ferraccioli (Italy), W Boehncke (Switzerland)  
P Emery (UK), M Østergaard (Denmark)

15.40–16.00 *Coffee break*

Session 4:  
**Hot topics and challenges in spondyloarthritis**

Session chairs:  
P Emery (UK), F Van den Bosch (Belgium)

16.00–17.00 **Panel discussion:**  
1. How can we optimize the patient's journey through the spondyloarthritis treatment pathway?

Moderators: P Emery (UK), F Van den Bosch (Belgium)

2. How should we classify disease modification in spondyloarthritis?
3. What is the cost of treating spondyloarthritis optimally?

D Baeten (Netherlands), J Cañete (Spain)  
P Nash (Australia), G Ferraccioli (Italy)

Q&A session

Moderators: P Emery (UK), F Van den Bosch (Belgium)

Summary and close of Day 1

P Emery (UK), F Van den Bosch (Belgium)



# Take a closer look at the reality of SpA



**Spondyloarthritis Scientific Forum**  
04–05 December 2015

## DAY 2: 05 DECEMBER

08.00–08.30 *Coffee*

08.30–08.35 Welcome and overview of Day 2

P Emery (UK), F Van den Bosch (Belgium)

**Session 5:  
Advances in the management of axial spondyloarthritis**

Session Chairs:  
P Emery (UK), F Van den Bosch (Belgium)

08.35–10.00 Understanding axial spondyloarthritis: where are we now and where do we need to get to?

D Poddubnyy (Germany)

Debate: Non-radiographic axial spondyloarthritis: a part of the disease spectrum that should be managed aggressively

Pro: J Sieper (Germany)  
Contra: M Østergaard (Denmark)  
Moderators: P Emery (UK), F Van den Bosch (Belgium)

Treating to target in axial spondyloarthritis: concepts, evidence, and challenges

J Smolen (Austria)

Q&A session

Moderators: P Emery (UK), F Van den Bosch (Belgium)

10.00–10.20 *Coffee break*

10.20–11.25 Targeted therapies in axial spondyloarthritis: current options and future perspectives

J Sieper (Germany)

Radiographic progression: the new target for treatment?

D Poddubnyy (Germany)

Q&A session

Moderators: P Emery (UK), F Van den Bosch (Belgium)

**Session 6:  
Parallel workshop sessions: optimizing the management of spondyloarthritis in clinical practice**

(Delegates will attend 1 workshop of 45 mins in length, with 10 mins allowed to move from/to the plenary room. The most popular workshops from Day 1 will be run again on Day 2 to allow all delegates to attend)

11.25–12.20 **Workshop sessions:**

1. Practical guidance on using biologics in spondyloarthritis
2. Early diagnosis and treatment of spondyloarthritis
3. Treating to target and aligning regional treatment practices with international guidelines: challenges and perspectives
4. Imaging in spondyloarthritis: what to look for and pitfalls to avoid

J Cañete (Spain), D Poddubnyy (Germany)  
P Emery (UK), F Van den Bosch (Belgium)  
J Sieper (Germany), P Nash (Australia)  
M Østergaard (Denmark)

**Closing Session:**

12.20–13.00 Keynote lecture: personalized medicine in inflammatory rheumatic conditions

J Smolen (Austria)

Summary and meeting close

P Emery (UK), F Van den Bosch (Belgium)

13.00–14.00 *Lunch*



**Status of Excellent Scientific Interest** attributed by the Spanish Society of Rheumatology (SER)

**Spondyloarthritis Scientific Forum** has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 10 category 1 (external) CPD credit(s). **RCP Activity Code: 101040**